SAN DIEGO, May 10 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. will be presenting at the Rodman & Renshaw 3rd Annual Global Healthcare Conference on Tuesday, May 16, 2006 at 1:00 PM Central Europe Time. Michael Grey, president and chief executive officer of SGX Pharmaceuticals, will provide a corporate overview including information on the Company’s lead drug candidate, Troxatyl(TM), currently in a pivotal Phase II/III trial for the treatment of third-line acute myelogenous leukemia, and highlights of the Company’s strategic collaboration with Novartis to develop BCR-ABL inhibitors for the treatment of drug resistant chronic myelogenous leukemia. The Rodman & Renshaw Conference is being held May 15-16 in Monte Carlo, Monaco.
A live webcast of the presentation will be available under the investor relations section of the Company’s website at www.sgxpharma.com. Replays of the presentation will be available for 90 days following the event. Please connect to the Company’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About SGX Pharmaceuticals
SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The lead product candidate, Troxatyl(TM), is currently being evaluated in a pivotal Phase II/III trial for the treatment of third-line acute myelogenous leukemia. SGX has developed a pipeline of oncology drug candidates based on its enabling, proprietary FAST(TM) drug discovery platform, including a portfolio of next generation BCR-ABL inhibitors currently being developed in partnership with Novartis. FAST allows for the rapid identification of novel, potent and selective small molecule compounds for well validated but challenging targets. More information on the pipeline and drug discovery platform can be found at www.sgxpharma.com.
Forward-looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to research and drug discovery and development programs, the effectiveness and efficiency of the FAST technology to generate novel lead molecules for therapeutic targets and the ability to discover, develop and commercialize cancer therapeutics. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, collaborations with others, and litigation. In particular, the results of early clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its product candidates will have favorable results in future clinical trials or receive regulatory approval. For a discussion of these and other factors, please refer to the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2005 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
SGX Pharmaceuticals, Inc.
CONTACT: Todd Myers, Chief Financial Officer of SGX Pharmaceuticals,+1-858-228-1565; or Jason Spark, Media & Investor Relations of PorterNovelli Life Sciences, +1-858-527-3491, for SGX Pharmaceuticals, Inc.
Web site: http://www.sgxpharma.com/
